Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 10.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 218,273 shares of the company's stock after purchasing an additional 19,973 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in Kenvue were worth $4,660,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Grove Bank & Trust boosted its stake in shares of Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after acquiring an additional 947 shares in the last quarter. Riverview Trust Co purchased a new position in Kenvue in the 3rd quarter valued at about $30,000. Geneos Wealth Management Inc. purchased a new position in Kenvue in the 4th quarter valued at about $29,000. Ashton Thomas Securities LLC purchased a new position in Kenvue in the 3rd quarter valued at about $35,000. Finally, Fortitude Family Office LLC lifted its stake in Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after buying an additional 777 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.
Kenvue Trading Up 0.2 %
Shares of NYSE KVUE traded up $0.05 during midday trading on Wednesday, reaching $20.96. 10,316,961 shares of the stock were exchanged, compared to its average volume of 12,673,827. The company has a 50 day simple moving average of $21.41 and a 200 day simple moving average of $22.03. The stock has a market capitalization of $40.19 billion, a P/E ratio of 39.55, a PEG ratio of 2.16 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46.
Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, equities analysts expect that Kenvue Inc. will post 1.05 earnings per share for the current year.
Kenvue Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.91%. Kenvue's dividend payout ratio (DPR) is presently 154.72%.
Analyst Ratings Changes
A number of research analysts recently weighed in on KVUE shares. UBS Group decreased their price target on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. Canaccord Genuity Group decreased their price target on shares of Kenvue from $27.00 to $24.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a "buy" rating to a "hold" rating and decreased their price target for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Piper Sandler raised shares of Kenvue from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. Finally, Barclays decreased their target price on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a research note on Friday, January 17th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, Kenvue has a consensus rating of "Hold" and an average target price of $23.00.
Read Our Latest Research Report on KVUE
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
